Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Precigen Inc (PGEN)

Precigen Inc (PGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,560,368
  • Shares Outstanding, K 353,825
  • Annual Sales, $ 3,930 K
  • Annual Income, $ -126,240 K
  • EBIT $ -108 M
  • EBITDA $ -97 M
  • 60-Month Beta 1.10
  • Price/Sales 208.09
  • Price/Cash Flow N/A
  • Price/Book 29.46

Options Overview Details

View History
  • Implied Volatility 116.07% (+33.44%)
  • Historical Volatility 72.60%
  • IV Percentile 56%
  • IV Rank 12.33%
  • IV High 500.18% on 04/14/25
  • IV Low 62.04% on 05/16/25
  • Expected Move (DTE 32) 0.34 (7.71%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 2,565
  • Volume Avg (30-Day) 1,656
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 65,141
  • Open Int (30-Day) 65,298
  • Expected Range 4.07 to 4.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.12
  • Prior Year -0.04
  • Growth Rate Est. (year over year) -125.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.78 +16.67%
on 12/17/25
4.95 -10.91%
on 01/07/26
+0.54 (+13.95%)
since 12/16/25
3-Month
3.39 +30.09%
on 10/17/25
5.19 -15.03%
on 11/14/25
+0.92 (+26.36%)
since 10/16/25
52-Week
1.08 +308.33%
on 01/17/25
5.22 -15.60%
on 09/03/25
+3.30 (+297.30%)
since 01/16/25

Most Recent Stories

More News
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md. , Jan. 12, 2026 /PRNewswire/ --  Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 4.41 (+6.52%)
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md. , Jan. 5, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company advancing innovative precision medicines, today announced that Helen Sabzevari, PhD, President...

PGEN : 4.41 (+6.52%)
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

GERMANTOWN, Md. , Nov. 6, 2025 /PRNewswire/ --  Precigen, Inc.  (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the...

PGEN : 4.41 (+6.52%)
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

GERMANTOWN, Md. , Oct. 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives...

PGEN : 4.41 (+6.52%)
Precigen Announces Up to $125 Million Non-Dilutive Financing

$100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and...

PGEN : 4.41 (+6.52%)
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug

Shares of Precigen, Inc. PGEN have skyrocketed 144.4% in August so far, following the company's announcement of the FDA approval for Papzimeos (zopapogene imadenovec-drba) for the treatment of adults...

KNSA : 39.41 (+3.93%)
PGEN : 4.41 (+6.52%)
CRMD : 6.78 (-3.28%)
INO : 1.5200 (-3.80%)
Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

GERMANTOWN, Md. , Aug. 25, 2025 /PRNewswire/ --  Precigen, Inc.  (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to...

PGEN : 4.41 (+6.52%)
Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

GERMANTOWN, Md , Aug. 15, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve...

PGEN : 4.41 (+6.52%)
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

Shares of Precigen PGEN have soared nearly 43% in the past week after the company provided an encouraging regulatory update for its lead pipeline program.Last week, Precigen announced that it has completed...

CTMX : 5.39 (+26.82%)
PGEN : 4.41 (+6.52%)
CSTL : 40.01 (-1.82%)
INO : 1.5200 (-3.80%)
Precigen Completes Regulatory Filing For Approval Of Gene Therapy To Treat Respiratory Papillomatosis: Retail Sentiment Surges Amid Stock Rally

Recurrent respiratory papillomatosis is a rare condition when benign tumors called papillomas grow in the respiratory tract, most commonly in the larynx.

IWC : 171.05 (+0.19%)
PGEN : 4.41 (+6.52%)
IBB : 169.96 (-0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional...

See More

Key Turning Points

3rd Resistance Point 4.86
2nd Resistance Point 4.65
1st Resistance Point 4.53
Last Price 4.41
1st Support Level 4.20
2nd Support Level 4.00
3rd Support Level 3.88

See More

52-Week High 5.22
Last Price 4.41
Fibonacci 61.8% 3.64
Fibonacci 50% 3.15
Fibonacci 38.2% 2.66
52-Week Low 1.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar